Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Glioblastoma
NCT00921167Phase 2Completed
- Sponsor
- Clinical Research Center for Solid Tumor
- Start
- Jun 2009
- Primary completion
- Jun 2012
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in anaplastic astrocytoma (AA) and glioblastoma (GBM), sponsored by Clinical Research Center for Solid Tumor. Primary endpoint: Progression-free survival at 1 year. Started Jun 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
anaplastic astrocytoma (AA)glioblastoma (GBM)
Beyond the preview
Go deeper on NCT00921167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921167.